TREM1 Blockade Ameliorates Lipopolysaccharide-Induced Acute Intestinal Dysfunction through Inhibiting Intestinal Apoptosis and Inflammation Response

Figure 3

LP17 reduces inflammatory response and activation of the NF-κB signaling in LPS-induced acute intestinal dysfunction rats. (a–d) The levels of (a) soluble TREM1 (sTREM1; ), (b) TNF-α (), (c) IL-6 (), and (d) IL-1β () in the plasma samples of rats from the indicated groups at 36 h after LPS treatment for 3 days were measured by ELISA. (e–h) The levels of (e) sTREM1 (), (f) TNF-α (), (g) IL-6 (), and (h) IL-1β () in the intestine tissue samples of rats from the indicated groups at 36 h after LPS treatment for 3 days were measured by ELISA. (i–k) The mRNA levels of (i) NF-κB (), (j) HMGB1 (), and (k) TLR-4 () in the small intestine tissues of rats from the indicated groups at 36 h after LPS treatments for 3 days were determined by RT-qPCR. for the normal group; for the model group; for the LP17 group. (l) Representative images of western blot results for NF-κB, HMGB1, and TLR-4 in the small intestine tissues of rats from the indicated groups. (m–o) The expression levels of (m) NF-κB (), (n) HMGB1 (), and (o) TLR-4 () proteins were quantified according to the western blot results. One-way analysis of variance (ANOVA) was used for multiple comparisons, followed by Tukey’s test. ; ; ; .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)